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Abstract 
 
Background: The effectiveness of aspirin and clopidogrel in patients with chronic 
kidney disease (CKD) suffering acute cardiovascular events (ACE) is unclear. High 
on treatment platelet reactivity (HTPR) has been associated with worse outcomes. 
Here we assessed the association of dipstick proteinuria (DP) and renal function on 
HTPR and clinical outcomes.   
Methodology: Retrospective cohort analysis of 261 consecutive, non-dialysis patients 
admitted for ACE (acute coronary syndrome or stroke) that had VerifyNow P2Y12 
and VerifyNow Aspirin assays performed. HTPR was defined as P2Y12 reactivity 
unit (PRU)>208 for clopidogrel and aspirin reaction units (ARU)>550 for aspirin. 
Renal function was classified based on estimated glomerular filtration rate (eGFR) 
and dipstick proteinuria was defined as ≥ 30 mg/dL of albumin detected on a spot 
analysis. All cause mortality, readmissions, and cardiac catheterizations were 
reviewed over 520 days. 
Results: In patients on clopidogrel (n=106), DP was associated with HTPR, 
independent of eGFR, diabetes mellitus, smoking or use of proton pump inhibitor  
(AOR=5.2, p=0.017). In patients with acute coronary syndromes, HTPR was 
associated with more cardiac catheterizations (p=0.009) and readmissions (p=0.032), 
but no differences in in-stent thrombosis or re-stenosis were noted in this cohort. In 
patients on aspirin (n=155), no associations were seen between DP and HTPR. 
However, all cause mortality was significantly higher with HTPR in this group 
(p=0.038). 
Conclusion: In this cohort, DP is an independent predictor of HTPR in patients on 
clopidogrel, but not aspirin, admitted to the hospital for ACE. 
Introduction 
 
Randomized clinical trials confirm the benefits of antiplatelet therapy in both primary 
and secondary prophylaxis of acute cardiovascular events (ACE)1,2. Aspirin, an 
irreversible cyclooxygenase inhibitor, and clopidogrel, an adenosine diphosphate 
receptor inhibitor, are the two most widely used antiplatelet medications3. High on 
treatment platelet reactivity (HTPR) in both antiplatelet agents has been associated 
with worse outcomes in patients with acute coronary syndromes (ACS) and in those 
undergoing percutaneous coronary interventions (PCI)4-7.  
The benefit and effect of antiplatelet therapy in patients suffering chronic kidney 
disease (CKD) remains unclear due to their exclusion from many clinical trials8. 
Recent studies have suggested possible links between CKD based on the extent of 
estimated glomerular filtration rate (eGFR) impairment, with HTPR9-11. However, 
given the diversity in kidney disease pathogenesis, whether this link was due directly 
to the eGFR, or other underlying pathophysiological events remains unknown. 
 Albuminuria is considered an important predictor of endothelial dysfunction and 
systemic inflammation, regardless of the degree of renal impairment, and is also a 
major predictor of cardiovascular morbidity and mortality, especially in diabetic 
patients12-14. In this study we assessed the relationship between renal function and 
albuminuria as detected on a spot urine dipstick on platelet reactivity and clinical 
outcomes. 
  
Methods 
Patients and Selection Criteria 
Two hundred eighty five consecutive adult patients who had on treatment platelet 
function measurement at the time of admission to Einstein Medical Center 
(Philadelphia, PA) for acute cardiovascular events (ACE) between January 1st 2012 
and March 31st 2013 were studied retrospectively. Patients were identified using 
ICD-9 codes at the time of admission and electronic medical records were extensively 
reviewed for confirmation. Although platelet reactivity is not routinely performed in 
our institution, the decision to undergo testing was driven by the physician on record 
based on his/her clinical decision-making. All patients were receiving aspirin (81 to 
325 mg) and/or clopidogrel (75 mg) according to their home medication list and 
pharmacy records when available at the time of the admission. Subjects were grouped 
based on the platelet reactivity test performed at the time of admission even if they 
were taking both aspirin and clopidogrel. All other variables such as past medical 
history, smoking history and other medications were gathered using electronic 
medical records. Exclusion criteria were ongoing dialysis, history of renal 
transplantation, active liver disease or cirrhosis, quantitative (≤150, 000) or qualitative 
platelet dysfunction (known bleeding disorder, thrombophilia), exposure to 
erythropoiesis stimulating agents, blood products transfusion including platelets, 
documented loading dose of P2Y12 antagonist at the time of platelet reactivity 
testing, and active bleeding during hospital stay. The institutional review board at 
Einstein Medical Center approved the study. No extramural funding was used to 
support this work.   
 
Platelet Function Assays and Definition 
Platelet function was assessed using the VerifyNow Aspirin and VerifyNow P2Y12 
analyzers (Ultegra Rapid Platelet-Function Assay; Accumetrics, San Diego, CA). 
These are point of care systems that measure rate and extent of light changes in whole 
blood as platelets aggregate over time in response to agonists that are specific to 
various antiplatelet medications (arachidonic acid and ADP, respectively for aspirin 
and clopidogrel). Results are reported as P2Y12 reactivity units (PRU) for clopidogrel 
and aspirin reactivity units (ARU) for aspirin.  HTPR was defined based on recent 
published data as PRU>208 for clopidogrel and ARU >550 for aspirin15. Blood 
sampling and platelet reactivity assays were performed following original protocols; 
whole blood was collected from venous sites using 21 gauge or larger needle in a 
partial fill; 3.2 % citrate vacuum collection tube (blue top), samples were obtained 
from extremities free of peripheral venous infusions and set a minimum of 30 minutes 
after collection before test was done but no longer than 4 hours.  
 
Renal Function and Proteinuria  
Renal function was classified based on estimated glomerular filtration rate (eGFR) 
using the serum creatinine at the time of platelet reactivity measurement. Albuminuria 
was detected based on a spot urine dipstick analysis at the time of admission. The 
dipstick urine test is a simple method of assessing overt albuminuria16. While the semi 
quantitative ability to assess the degree of albuminuria with a spot dipstick is limited 
by the specific gravity at the time of the test, given the retrospective nature of this 
study we used a cutoff of urine dipstick protein of >30 mg/dl (>300 to 500 mg/g on a 
spot-protein/creatinine ratio), to identify subjects with overt proteinuria, as 
microalbumin/creatinine ratios were not uniformly available in this cohort of patients. 
For final analysis, patients were classified into two groups; eGFr> 60 cc/min and 
eGFR< 60 cc/min.  
 
Clinical Definition and Outcome Measurement 
Patients admitted with ACE comprised acute coronary syndromes (unstable angina 
and myocardial infarction), cerebrovascular accidents (cerebrovascular accident and 
transient ischemic attack), and cardiovascular death. All cause mortality events 
reported in the Social Security Death Master File were recorded until December 31st 
2013.Thirty-day readmission rate due to ACE, length of stay (LOS), percutaneous 
coronary intervention, and incidence of stent thrombosis or re-stenosis were reviewed 
with a mean follow up of 520 days.  
 
Statistical analysis 
Student t-tests (two-tailed) and Mann-Whitney tests (two-tailed) were used to 
compare various clinical parameters, and Bonferroni correction was applied to adjust 
for multiple comparisons. Fisher’s exact test was used to compare the percentage of 
patients with PRU >208 among the patient subgroups with and without DP 
Likelihood ratio p value was computed to compare the percentage of patients with 
PRU >208 among the patients with different eGFrs. Multivariate analysis was done 
using a logistic regression model to adjust the effects eGFr and DP on PRU binary 
outcome (>208 or ≤208) and calculate the adjusted odds ratios. All the analyses were 
done using JMP 10.0 (SAS, Cary, NC) and PRISM 6.0 (GraphPad Software Inc., La 
Jolla, CA) softwares.  
Results 
Cohorts Characteristics 
A total of 261 of 285 patients studied qualified for final analysis, with 24 patients 
excluded from analysis for the following reasons: 2 patients had underlying cirrhosis 
while on antiplatelet medication, 9 patients were tested for platelet function despite no 
documentation of being on antiplatelet therapy based on outpatient and pharmacy 
records, 1 patient required transfusion of blood products, 7 patients were loaded with 
clopidogrel at the time of admission, and 5 blood samples were stored inappropriately 
resulting in in-vitro interaction and mistaken results according to the laboratory 
report.  
Baseline demographic data and clinical characteristics of patients (based on their 
antiplatelet assay and HTPR status) are listed in Table 1. In our cohort 106 (40.6%) 
patients taking daily clopidogrel were assayed for platelet function expressed as PRU, 
whereas 155 (59.4%) patients taking daily aspirin were assayed for platelet function 
expressed as ARU. HTPR was found in 60.4% of patients taking clopidogrel (PRU 
>208, n=64), but only 16.1% of patients taking aspirin (ARU >550, n=25). Eighty 
seven percent (n=92) of the subjects on clopidogrel were also on aspirin, and 32% 
(n=49) of patients on aspirin were taking clopidogrel as well. There were no 
significant differences in clinical characteristics between subgroups, except subjects 
with an ARU >550 had a higher eGFR than patients with an ARU ≤550 (p=0.01). 
Forty two percent of patients with PRU >208 had evidence of DP (n=27) whereas 
13% of patients with PRU≤208 (n=5) had DP at the time of the assay (p=0.01). When 
considering PRU as a continuous variable, there was a mild but significant association 
between PRU and HbA1c (p=0.02, r2=0.07).  
  
Association of Dipstick Proteinuria and Renal Function on HTPR  
In patients on clopidogrel, DP was associated with PRU >208 (OR=4.93, Fisher’s 
exact p=0.015, Table 2 and Figure 1). Renal function was not associated with PRU 
values either when assessed using eGFR as a continuous score (using either MDRD or 
CKD-EPI creatinine formula when appropriate, data not shown). However, the 
prevalence of HTPR was 100% in eGFr< 30 cc/min (n=8, 7 had DP). 
In multivariate analysis shown in Table 2, the association between DP and PRU were 
adjusted for multiple variables (eGFR, diabetes mellitus, history of smoking or use of 
protein pump inhibitors), using a logistic regression model, also eGFR calculation 
takes into account age, gender and race. For this purpose we grouped our sample into 
eGFr> 60 cc/min and eGFR< 60 cc/min. Here, DP, but not eGFR, remained 
significantly associated with PRU >208 in the multivariate model (adjusted OR=5.2, 
p=0.017, Table 2).  
In contrast, DP and eGFR did not demonstrate a significant association with HTPR in 
patients on aspirin. The eGFR
 
were significantly higher in ARU >550 (p=0.01, Table 
1).  
 
HTPR and Clinical Outcomes 
In our cohort, HTPR in patients on clopidogrel was not associated with the following 
outcomes: all cause mortality, LOS in hospital, 30 days readmission due to ACE, 
number of coronary interventions, in-stent thrombosis, in-stent stenosis (Table 1). In 
contrast, HTPR in patients on aspirin was significantly associated with higher all 
cause mortality (5% versus 16%, p=0.038). 
However, in sub-analysis focusing on patients receiving clopidogrel who were 
admitted with either non ST segment myocardial infarction or ST segment myocardial 
infarction (51.9%, n=45 and n=10 respectively), there was a significant correlation 
between HTPR in patients and subsequent number of coronary catheterizations during 
the follow up period (p=0.009, r2=0.13, 95% CI for slope =0.002 to 0.011, Figure 2). 
In addition, HTPR was significantly associated with 30 days readmission for MACE 
in this subgroup (p=0.03, r2=0.08). 
 
  
Discussion 
The major finding of this study is that the presence of DP (≥300 mg/g), independent 
of eGFR, is strongly associated with HTPR in patients on clopidogrel, but not in those 
on aspirin. In particular, after adjusting for potential cofounders, patients with DP had 
a 5-fold increase in the odds of having HTPR while on clopidogrel when compared 
with those without DP. While platelet reactivity is a metric of thrombosis and cardiac 
catheterization is a clinical driven decision, our data does suggest a modest 
association between HTPR and subsequent cardiac catheterizations, in the sub group 
of patients admitted with ACS.    
Up to one third of patients treated with clopidogrel do not display an adequate 
antiplatelet response17. In contrast, the prevalence of non-responders to aspirin is as 
low as 0 to 20%, and its clinical significance is debatable4,18,19. Routine platelet 
function testing is not currently recommended and is considered a class IIB indication 
in high risk patient undergoing PCI and those prone to recurrent events according the 
American College of Cardiology Foundation/American Heart Association  Task Force 
and the Society for Cardiovascular Angiography and Interventions20,21. Recently, the 
largest prospective multicenter registry on platelet reactivity and clinical outcomes 
after coronary artery implantation of drug-eluting stents (ADAPT-DES) showed that 
PRU after PCI was strongly related to subsequent stent thrombosis, and that adopting 
a cutoff value of >208 would reclassify the risk of definite stent thrombosis for 35% 
of the patients [unadjusted HR 2.54 (95% CI 1.55-4.16) p=0.0002]15. Thus, a recent 
consensus has adopted this new cutoff value as the marker of HTPR22,  
Even subtle decrement in GFR is an independent risk factor for accelerated 
atherosclerosis and thrombotic events23,24. Although there are contrasting data, 
previous studies have linked CKD to HTPR putting patients in a higher risk 
category9,11,25. A potential explanation for an abnormal response to ADP antagonist 
therapy in patients with CKD is an increased expression of multiple signaling 
pathways, higher levels of C-reactive protein, von Willenbrand factor and soluble P-
selectin resulting in platelet hyper reactivity26,27. Conversely, there is also some 
evidence that GFR decline may not be associated with HTPR28.  
Albuminuria precedes renal function decline and has been used as a surrogate of 
systemic inflammation and endothelial dysfunction, it is considered a strong 
independent risk for cardiovascular events regardless of its association with other well 
known risk factors for ACE such as hypertension and diabetes12,13,29. Recently it was 
associated with an increase risk of Periprocedural Myocardial Injury in Patients 
Undergoing Elective Coronary Stent Implantation30. Furthermore, reduction of 
albuminuria is associated with a decreased occurrence of ACE31. Araki et al 
demonstrated an independent association between albuminuria and early changes in 
activated platelet profiles of type 2 diabetic patients32. These patients were not on any 
ADP inhibitors and the association between albuminuria and HTPR was not assessed. 
Moreover, no analysis was perform based on eGFR and albuminuria.   
The results presented in this study to our knowledge, are the first data to delineate an 
association between dipstick proteinuria and platelet reactivity, regardless of GFR 
quantification on single or dual antiplatelet therapy. We acknowledge that assessment 
of proteinuria with a dipstick is a "snapshot" view and that given the low number of 
events we cannot conclude any associations between HTPR and individual events. 
Larger studies are needed to establish this relationship. However our data does 
suggest that even a one time assessment of proteinuria in the setting of ACE, might 
have prognostic and therapeutic implications, including stepping up antiproteinuric 
therapy to optimize platelet inhibition in high risk patients.  
Interestingly Tu et al suggested that the combination of clopidogrel and angiotensin 
receptor blocker (Ibersantan) attenuated the progression of CKD including proteinuria 
through platelet inhibition and anti-inflammatory effects resulting in decreased 
glomerular fibrosis33. In addition, even in the non proteinuric patient at baseline, 
transient "stress related proteinuria" is well documented in the setting of critical 
illness, possible mechanisms including; capillary leak, endothelial injury and early 
tubular injury34. Thus, even if not detected in longitudinal studies, the association of 
HTPR with proteinuria at the time of ACE in itself might have prognostic 
implications.   
Study Limitations 
There are several limitations to consider in the interpretation of our findings. The 
current data derived from the observational study design do not permit causal 
inference among the reported associations, but rather are useful for hypothesis 
generation. Our criteria for selection of subjects included those with available data on 
platelet reactivity, which may represent a high-risk subset of patients to begin with. 
Although we attempted to assure compliance with antiplatelet medication by 
acquiring information from outpatient and pharmacy records, non-compliance could 
potentially explain the associations between DP, renal function and platelet reactivity. 
The association between DP and HTPR is limited by our small sample size, and larger 
studies are needed to confirm whether or not this association is in fact reproducible. 
We cannot exclude the possibility that other unmeasured confounders, including 
genetic polymorphisms, and other non-documented medications such as over the 
counter non-steroidal anti-inflammatory drugs or undiagnosed conditions like 
underlying malignancy might contribute to our findings. In addition, while dipstick 
assessment of albuminuria semi quantitatively is a useful and widely available 
screening tool, the accuracy is limited by the lack of precise quantification such as a 
spot albumin to creatinine ratio, or a 24-hour urine collection for albumin excretion 
and variations inspecific gravity at the time of testing. We cannot exclude with 
certainty the possibility of in vitro interaction in patients on simultaneous dual anti 
platelet therapy, even though the pharmacodynamics and pathways of platelet 
inhibition are different. Our analysis of clinical outcomes was limited to all-cause 
mortality, readmission to a single institution and number of interventions done by a 
single center cardiology practice. 
 
Conclusions 
To our knowledge this is the first study reporting an association between  
dipstick proteinuria and platelet reactivity. Here DP is independently associated with 
HTPR in patients taking clopidogrel; however this association was not seen in 
patients on aspirin. HTPR in patients on clopidogrel was associated with an increased 
rate of cardiac catheterizations and cardiovascular readmissions. Although the 
prevalence of aspirin resistance was low, it was significantly associated with all cause 
mortality. 
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Table and Figure Legends 
 
Table 1: Demographics and Baseline Characteristics of Patients at the Time of 
Admission Grouped by Antiplatelet Therapy and Platelet Reactivity Assay  
 
Figure 1: The Separate Relationships of Estimated Glomerular Filtration Rate and 
Dipstick Proteinuria with HTPR in ACE Patients Treated with Clopidogrel 
Footnote for Figure 1: 
Column graph demonstrating prevalence of HTPR across patients grouped based on 
eGFR ≥60 ml/min/1.73m2 and eGFR <60 ml/min/1.73m2 and the presence of DP. 
HTPR is defined as PRU>208 for clopidogrel. Renal function was defined by 
estimated GFR calculated using Modification of Diet in Renal Disease (MDRD) 
equation that calculates creatinine clearance based on patient's gender, age and 
ethnicity. Spot Dipstick Proteinuria (DP) was defined as dipstick protein of >30 mg/dl 
(>300 to 500 mg/g on a spot-protein/creatinine ratio. Fisher's exact test was used to 
analyze the differences of HTPR prevalence across DP status. 
 
Table 2: Multivariable Logistic Regression Model Study of Factors Associated with 
High on Treatment Platelet Reactivity.  
 
Figure 2: Linear regression between platelet reactivity unit (PRU) and number of 
cardiac catheterization in patients presenting with acute coronary syndrome (ACS) 
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Table 1 
Table 1: Demographics and Baseline Characteristics of Patients at the 
Time of Admission Grouped by the Antiplatelet Treatment and Platelet 
Reactivity Assay  
 
Patients on clopidogrel Patients on aspirin 
  
All 
subjects 
(n=106) 
PRU ≤ 
208 
(n=42) 
PRU > 
208 
(n=64) 
All 
subjects 
(n=155) 
ARU ≤ 
550 
(n=130) 
ARU > 
550 
(n=25) 
Demographics 
  
  
   
    Mean age (y±SD) 63.4 ± 12.3 
65.1 ± 
12.7 
62.3 ± 
12.0 
67.3 ± 
13.3 
67.4 ± 
12.9 
66.4 ± 
15.9 
    Gender (% male) 49.1 50 48.4 38.1 36.9 44 
Past medical 
history        
    Hypertension (%) 92.4 88.1 95.3 90.9 90.8 92 
    Diabetes (%) 60 54.7 63.4 52.3 52.3 52 
    CAD (%) 80.9 88.1 76.1 34.2 33 44 
    PVD (%) 22.1 33.3 14.5 10.4 11.5 4.2 
    PCI (%) 71.4 76.1 68.2 18.2 20.8 4.2 
    CABG (%) 17.1 19 15.8 6.5 6.9 4.2 
    TIA or CVA (%) 48.1 42.8 51.6 85.8 79.2 80 
    CHF (%) 31.3 40 25.4 18.8 19.8 13 
    Smoking (%) 41.5 40.4 42.1 36.2 35.2 41.7 
Medical therapy 
  
  
   
    Median 
medications (n) 9 10 9 8 8 8 
    Aspirin (%) 86.7 83.3 89.1 100 100 100 
    Clopidogrel (%) 100 100 100 32.3 31.5 36 
    PPI (%) 35.8 28.5 40.6 30.5 28.7 40 
    ACE-I or ARB (%) 68.8 73.8 65.6 59.4 56.9 72 
    Beta-blocker (%) 75.4 76.1 75 45.8 42.3 64 
    Statin (%) 92.5 90.4 93.7 82.6 83.1 80 
    Loop diuretics (%) 44.3 45.2 43.7 37.4 38.5 32 
Clinical data 
  
  
   
    Creatinine (mg/dL) 1.2± 0.7 1.1± 0.3 1.3± 0.9 1.2±0.6 1.2±0.6 1.0±0.4 
    eGFRMDRD (mL/min) 77.8 ± 36.9 
80.2 ± 
40.7 
76.2 ± 
34.4 
78.8 ± 
38.0 
75.4 ± 
32.9 
 96.4 ± 
54.5 * 
    eGFRCKD-EPI Creatinine 
(mL/min) 
71.7 ± 
28.7 
72.6 ± 
26.0 
71.0 ± 
30.6 
71.0 ± 
27.9 
69.0 ± 
27.5 
 81.5 ± 
28.5 * 
    Dipstick 
Proteinuria (%) 34.7 13 
       42.6 
* 
33.8 34.5 26.3 
    Median LV-EF (%) 55 50 55 55 55 55 
    HbA1C (%) 7.6± 2 7.2± 2 7.8 ±2 7.2±1.9 7.3±1.7 7±2.5 
Outcomes 
  
  
   
    All cause mortality 
(%) 8.4 7.1 9.3 5.8 5 
         16 
* 
    LOS in hospital 
(days) 5.5 4.5 6.2 4.1 4.2 3.6 
    30 days 
readmissions (n) 2.1 1.7 2.3 1.3 1.3 1.5 
    DVT or PE (%) 1.8 0 3.1 7.7 6.2 16 
    Coronary 
catheterizations (n) 2.4 2.3 2.5 1.7 1.7 1.3 
    In-stent stenosis 
(%) 38.1 41.4 35.3 14.8 16.7 0 
    In-stent thrombosis 
(%) 13.6 11.5 15.2 0 0 0 
Note: * denotes p<0.05 when compared the subgroups in bold 
Abbreviations: ACE-I = angiotensin-converting-enzyme inhibitor;  ARB = angiotensin II receptor 
blockers;  ARU = aspirin reactivity unit;  CABG = coronary artery bypass graft;  CAD = 
coronary artery disease;  CHF = congestive heart failure;  CVA cerebrovascular accident;  DVT 
= deep vein thrombosis;  eGFRCKD-EPI Creatinine = estimated glomerular filtration rate (Chronic 
Kidney Disease Epidemiology Collaboration formula);  eGFRMDRD = estimated glomerular 
filtration rate (Modification of Diet in Renal Disease formula);  HbA1c = hemoglobin A1c;  LOS 
= length of stay;  LV-EF = left ventricular ejection fraction;  PCI = percutaneous coronary 
intervention;  PE = pulmonary embolism;  PPI = protein pump inhibitor;  PRU = platelet 
reactivity unit;  PVD = peripheral vascular disease; TIA = transient ischemic attack 
 
  
Table 2 
Table 2. Logistic regression analysis of PRU on CKD and proteinuria 
PRU (n) univariate Multivariate (n=69) 
>208 <208 OR (95% CI) p AOR (95% CI) p 
CKD stage 
(n=106) 
1-2 44 30 
0.76 
      
0.62 3-5 20 12 1.13 (0.48-2.77) 0.72 (0.19-2.62) 
proteinuria>30 
(n=70) no 27 20 
0.015 0.017 yes 20 3 4.93(1.44-23.02) 5.2 (1.31-28.11) 
DM (n=105) no 23 19 
yes 40 23 1.43 (0.64-3.19) 0.37 1.70 (0.58-5.09) 0.33 
on a PPI (n=106) no 38 30 
yes 26 12 1.71 (0.75-4.03) 0.20 1.91 (0.63-6.30) 0.25 
Smoker (n=106) no 37 25 
yes 27 17 1.07(0.48-2.38) 0.86 1.19 (0.39-3.70) 0.75 
PRU=P2Y12 Reactivity Units, CKD=Chronic Kidney Disease, OR=Odds Ratio, 
AOR=Adjusted Odds Ratio, PPI=Proton Pump Inhibitor, DM=Diabetes Mellitus 
 
